SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Clinical trials for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug called TAK-186 in adults with advanced head and neck, lung, or colorectal cancer that could not be removed by surgery. The main goals were to check for side effects and find the best dose. The trial was stopped early, but the results help researchers …
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 01:05 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients
Disease control TerminatedThis study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC